Sentio BioSciences, a vertically integrated pharmaceutical manufacturer specializing in generic drugs, announced plans to expand its Maryland Heights, Missouri operations with an investment exceeding $10.6 million and the creation of 58 new jobs. The expansion represents a significant commitment to domestic pharmaceutical manufacturing capacity, scheduled for completion in 2026.
Manufacturing Capacity Enhancement
The investment will substantially increase Sentio's capacity for domestic manufacturing of generic medicines, encompassing key starting materials, Active Pharmaceutical Ingredients (APIs), and finished drug products. The company currently manufactures three products and is in the process of submitting a fourth product to the FDA for approval.
"Sentio has been a strong advocate for manufacturing essential medicines in the United States, emphasizing high quality, secure and reliable supply," said Karthik Raghavan, CEO of Sentio BioSciences. "This expansion announcement shows our continued commitment and builds on our successful track record for manufacturing essential medicines domestically."
Contract Services Expansion
The expanded facility will include infrastructure to support contract development and manufacturing services (CDMO) for both innovators and established life sciences companies located in Missouri and throughout the United States. This diversification positions Sentio to serve a broader range of pharmaceutical development and manufacturing needs beyond its current generic drug portfolio.
Workforce Development and Safety Recognition
Sentio has implemented comprehensive workforce development programs, including on-the-job training and upskilling initiatives targeting non-traditional talent pools. These programs transform individuals into skilled pharmaceutical technicians and analysts, addressing critical workforce needs in the pharmaceutical industry.
The company recently achieved certification through the Occupational Safety and Health Administration's (OSHA) Safety and Health Achievement Recognition Program (SHARP). This certification recognizes Sentio as a model for worksite safety and health, available only to small employers with injury and illness rates below the national average who participate in Missouri's On-Site Safety and Health Consultation Program.
Economic Development Support
The expansion will benefit from Missouri's Works program, which provides companies access to capital through withholdings or tax credits for job creation. The program supports business expansion and worker retention initiatives across the state.
"Sentio BioSciences' expansion speaks to Missouri's ability to produce and support companies that transform industries and improve lives," said Michelle Hataway, Director of the Department of Economic Development. "We're proud to join our partners in ensuring this local employer, innovator, and job creator continues to help Missourians prosper."
Governor Mike Kehoe emphasized the strategic importance of the expansion, stating, "The St. Louis region stands out as a leading location for cutting-edge employers like Sentio BioSciences. This Missouri-made company's emphasis on innovation and safety aligns perfectly with our strengths in science, technology, and manufacturing."
The expansion reinforces Sentio's 16-year presence in Maryland Heights and its commitment to domestic pharmaceutical manufacturing, addressing supply chain security concerns while maintaining high-quality production standards for essential medicines.
